Freedom of Information request on all raw data submitted to the MHRA Yellowcard Reporting System regarding all Covid 19 Vaccines from 2019 until the current date (FOI 22/020)
Published 31 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-10-january-2022/freedom-of-information-request-on-all-raw-data-submitted-to-the-mhra-yellowcard-reporting-system-regarding-all-covid-19-vaccines-from-2019-until-the-c
FOI 22/020
10th January 2022
Dear,
Thank you for your Freedom of Information (FOI) request dated 6th January 2022 where you asked for the following:
“all raw data submitted to the MHRA Yellowcard Reporting System regarding all Covid 19 Vaccines from 2019 until the current date. The data should include all data submitted to this website: https://coronavirus-yellowcard.mhra.gov.uk/
We can confirm that we hold this data however patient information is exempt from release under Section 40 of the FOI Act which protects personal data, the disclosure of which would breach one or more of the data protection principles therefore we cannot provide individual case safety reports.
For COVID-19 vaccinations we are proactively publishing details of adverse drug reactions received, including MHRA assessment of the data to provide context. Please note this data is updated weekly.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division